Kan Gong

List of Publications by Year
in descending order

86 papers	1,817 citations	279798 23 h-index	315739 38 g-index
97 all docs	97 docs citations	97 times ranked	2742 citing authors

#	Article	IF	Citations
1	Natural history of Von Hippelâ€“Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2631-2641.	2.5	5
2	Belzutifan: a novel therapy for von Hippelâ€“Lindau disease. Nature Reviews Nephrology, 2022, 18, 205-206.	9.6	10
3	Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction. International Journal of Biological Sciences, 2022, 18, 2329-2344.	6.4	6
4	Elevated tumor markers for monitoring tumor response to immunotherapy. EClinicalMedicine, 2022, 46, 101381.	7.1	4
5	Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. Journal of Medical Genetics, 2022, 59, 951-956.	3.2	5
6	VHL Ser65 mutations enhance HIF2Î± signaling and promote epithelial-mesenchymal transition of renal cancer cells. Cell and Bioscience, 2022, 12, 52.	4.8	4
7	CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma. Epigenomics, 2021, 13, 31-45.	2.1	13
8	Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway. Cell Death and Disease, 2021, 12, 1.	6.3	223
9	Association between vasectomy and risk of prostate cancer: a meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 962-975.	3.9	4
10	HER2â€‘amplified metastatic lung adenocarcinoma responds to fourthâ€‘line pyrotinib therapy: A case report. Molecular and Clinical Oncology, 2021, 15, 213.	1.0	1
11	Serum carcinoembryonic antigen elevation in benign lung diseases. Scientific Reports, 2021, 11, 19044.	3.3	15
12	TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. Cancer Discovery, 2020, 10, 460-475.	9.4	63
13	Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippelâ€“Lindau disease: case report. BMC Medical Genetics, 2020, 21, 191.	2.1	3
14	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. Molecular Cell, 2020, 77, 1294-1306.e5.	9.7	41
15	The Genotype-Phenotype Association of Von Hipple Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population. Frontiers in Genetics, 2020, 11, 532588.	2.3	6
16	Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment. Hereditary Cancer in Clinical Practice, 2020, 18, 21.	1.5	1
17	Stereotactic radiosurgery for central nervous system hemangioblastoma in von Hippel-Lindau disease: A systematic review and meta-analysis. Clinical Neurology and Neurosurgery, 2020, 195, 105912.	1.4	6
18	Overexpression of EGFR and TGFÎ± in von Hippelâ€“Lindau-Related Central Nervous System Hemangioblastomas. Frontiers in Oncology, 2020, 10, 703.	2.8	5

#	Article	IF	Citations
19	Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. Journal of Medical Genetics, 2020, 57, 744-751.	3.2	1
20	Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. Aging, 2020, 12, 4424-4444.	3.1	31
21	The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippelâ€“Lindau Disease: A Retrospective Study of 32 Patients. Frontiers in Oncology, 2019, 9, 1122.	2.8	10
22	Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippelâ€“Lindau Disease. Frontiers in Genetics, 2019, 10, 867.	2.3	18
23	Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients. Frontiers in Oncology, 2019, 9, 1037.	2.8	10
24	Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors. Frontiers in Genetics, 2019, 10, 358.	2.3	4
25	Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharmacological Research, 2019, 144, 235-244.	7.1	124
26	Distinctive clinicopathological features of Vonï¿½Hippelâ€'Lindauâ€'associated hereditary renal cell carcinoma: A singleâ€'institution study. Oncology Letters, 2019, 17, 4600-4606.	1.8	3
27	Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients. Journal of Medical Genetics, 2019, 56, 380-387.	3.2	8
28	TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway. International Journal of Biological Sciences, 2019, 15, 587-597.	6.4	49
29	Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features. Clinical Genitourinary Cancer, 2019, 17, 97-104.e1.	1.9	7
30	Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma â€“ a retrospective study using TCGA database. Aging, 2019, 11, 1633-1647.	3.1	157
31	The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population. Journal of Evidence-Based Medicine, 2018, 11, 64-67.	2.4	14
32	Risk factors for survival in patients with von Hippel-Lindau disease. Journal of Medical Genetics, 2018, 55, 322-328.	3.2	26
33	68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1852-1861.	6.4	54
34	Genotype and phenotype correlation in von Hippelâ€“Lindau disease based on alteration of the HIF-Î± binding site in VHL protein. Genetics in Medicine, 2018, 20, 1266-1273.	2.4	37
35	Renal Arterial Pseudoaneurysm and Renal Arteriovenous Fistula Following Partial Nephrectomy. Urologia Internationalis, 2018, 100, 368-374.	1.3	11
36	Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 727-733.	1.2	7

#	Article	IF	Citations
37	VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma. International Journal of Oncology, 2018, 54, 390-398.	3.3	0
38	Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. Journal of Experimental and Clinical Cancer Research, 2018, 37, 276.	8.6	46
39	Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer Management and Research, 2018, Volume 10, 6627-6639.	1.9	18
40	Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases. World Journal of Surgical Oncology, 2018, 16, 16.	1.9	11
41	Novel germline mutations in FLCN gene identified in two Chinese patients with Birtâ€“Hoggâ€“DubÃ© syndrome. Chinese Journal of Cancer, 2017, 36, 4.	4.9	5
42	MP60-05 ERYTHROPOIETIN RECEPTOR MAY BECOME A TARGET FOR RENAL CELL CARCINOMA. Journal of Urology, 2017, 197, .	0.4	0
43	PD04-07 HIGHER PD-L1 MRNA LEVEL IN CLEAR CELL RENAL CELL CARCINOMAS IS ASSOCIATED WITH A FAVORABLE OUTCOME. Journal of Urology, 2017, 197, .	0.4	0
44	Clinicopathologic Features and Prognosis of Sporadic Bilateral Renal Cell Carcinoma: A Series of 148 Cases. Clinical Genitourinary Cancer, 2017, 15, 618-624.	1.9	14
45	Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience. World Journal of Surgical Oncology, 2017, 15, 4.	1.9	6
46	PD52-10 SHORTER TELOMERE LENGTH INCREASES AGE-RELATED TUMOR RISKS IN CHINESE VON HIPPLE-LINDAU DISEASE. Journal of Urology, 2017, 197, .	0.4	0
47	MP67-01 TELOMERE LENGTH AND GENETIC ANTICIPATION IN A LARGE COHORT OF CHINESE VON HIPPLE-LINDAU DISEASE. Journal of Urology, 2017, 197, .	0.4	0
48	MP67-19 THE NUCLEAR GRADE AND PROGNOSIS ARE UNRELATED TO THE TNM STAGE IN MULTILOCULAR CYSTIC RENAL CELL NEOPLASM OF LOW MALIGNANT POTENTIAL. Journal of Urology, 2017, 197, .	0.4	0
49	Shorter telomere length increases ageâ€related tumor risks in von Hippelâ€Lindau disease patients. Cancer Medicine, 2017, 6, 2131-2141.	2.8	17
50	Clinicopathologic characteristics, therapy and outcomes of patients with primary ureteral small cell carcinoma: a case series and systematic review of the literature. OncoTargets and Therapy, 2017, Volume 10, 4105-4111.	2.0	10
51	Vascular endothelial growth inhibitor 174 and its functional domains inhibit epithelial-mesenchymal transition in renal cell carcinoma cells in vitro. International Journal of Molecular Medicine, 2017, 40, 569-575.	4.0	1
52	Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. Oncotarget, 2017, 8, 3355-3363.	1.8	15
53	Fluorescencein situhybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. Oncotarget, 2017, 8, 26106-26111.	1.8	11
54	Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients. Oncotarget, 2017, 8, 38456-38465.	1.8	25

#	Article	IF	Citations
55	Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. Oncotarget, 2017, 8, 49839-49850.	1.8	24
56	Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma. Anticancer Research, 2017, 37, 4379-4388.	1.1	4
57	Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment. Juntendo Medical Journal, 2017, 63, 326-330.	0.1	0
58	Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelialâ€“Mesenchymal Transition in Renal Cell Carcinoma In Vivo. Anticancer Research, 2017, 37, 4269-4275.	1.1	1
59	Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma. Oncology Letters, 2016, 11, 4095-4098.	1.8	17
60	Multilocular Cystic Renal Cell Neoplasm of Low Malignant Potential: A Series of 76 Cases. Clinical Genitourinary Cancer, 2016, 14, e553-e557.	1.9	34
61	Comparison between completely and traditionally retroperitoneoscopic nephroureterectomy for upper tract urothelial cancer. World Journal of Surgical Oncology, 2016, 14, 171.	1.9	7
62	The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World Journal of Urology, 2016, 34, 871-877.	2.2	33
63	Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Molecular and Clinical Oncology, 2015, 3, 543-549.	1.0	6
64	Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics, 2015, 7, 733-744.	2.1	25
65	Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population1These authors contribute equally.. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 66.e1-66.e11.	1.6	21
66	Higher Prevalence of Novel Mutations in VHL Gene in Chinese Von Hippel-Lindau Disease Patients. Urology, 2014, 83, 675.e1-675.e6.	1.0	9
67	Telomere Shortening Is Associated with Genetic Anticipation in Chinese Von Hippelâ€“Lindau Disease Families. Cancer Research, 2014, 74, 3802-3809.	0.9	32
68	MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cellular Signalling, 2013, 25, 1212-1221.	3.6	59
69	739 CLINICAL CHARACTERISTICS OF VON HIPPEL-LINDAU DISEASE IN CHINESE PATIENTS. Journal of Urology, 2013, 189, .	0.4	0
70	Mosaicism in von Hippelâ€“Lindau disease with severe renal manifestations. Clinical Genetics, 2013, 84, 581-584.	2.0	17
71	Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide highâ€volume centre in <scp>C</scp>hina. BJU International, 2013, 112, 917-924.	2.5	63
72	Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor. International Journal of Oncology, 2013, 42, 1664-1673.	3.3	6

#	Article	IF	Citations
73	CSTP1, a Novel Protein Phosphatase, Blocks Cell Cycle, Promotes Cell Apoptosis, and Suppresses Tumor Growth of Bladder Cancer by Directly Dephosphorylating Akt at Ser473 Site. PLoS ONE, 2013, 8, e65679.	2.5	27
74	Family history of von Hippelâ€“Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. Journal of Human Genetics, 2012, 57, 238-243.	2.3	53
75	Cauda equinahemangioblastoma at L5 vertebral level related to von Hippelâ€“Lindau disease. British Journal of Neurosurgery, 2012, 26, 576-577.	0.8	5
76	Prognostic Factors in Chinese Patients With Penile Invasive Squamous Cell Carcinoma. Journal of Andrology, 2012, 33, 1276-1281.	2.0	4
77	Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention. Journal of Cancer Research and Clinical Oncology, 2012, 138, 269-274.	2.5	37
78	The Erythropoietin/Erythropoietin Receptor Signaling Pathway Promotes Growth and Invasion Abilities in Human Renal Carcinoma Cells. PLoS ONE, 2012, 7, e45122.	2.5	24
79	Comparison of laparoscopic and open cystectomy for bladder cancer: a single center of 110 cases report. Translational Andrology and Urology, 2012, 1, 4-8.	1.4	13
80	Extramammary Paget's disease of scrotumâ€”report of 25 cases and literature review. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 28-33.	1.6	58
81	The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1Î± and -2Î± in sporadic clear cell renal carcinoma. International Journal of Molecular Medicine, 2010, 26, 907-12.	4.0	13
82	Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. Journal of Cancer Research and Clinical Oncology, 2008, 134, 433-437.	2.5	34
83	THE RELATIONSHIP OF EPO OVER-EXPRESSION TO VHL MUTATIONS AND Hif1Î± AND 2Î± IN SCCRCC. Journal of Urology, 2008, 179, 91-91.	0.4	0
84	THE NATURAL HISTORY OF INCIDENTALLY DISCOVERED RENAL CELL CARCINOMAS (RCCS). Journal of Urology, 2008, 179, 332-333.	0.4	1
85	Coexpression of erythropoietin and erythropoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biology and Therapy, 2006, 5, 582-585.	3.4	18
86	Use of suppression subtractive hybridization strategy for cloning and identifying specifically expressed genes of renal cell carcinoma. Science Bulletin, 2001, 46, 226-229.	1.7	2